JP2003505362A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003505362A5 JP2003505362A5 JP2001511410A JP2001511410A JP2003505362A5 JP 2003505362 A5 JP2003505362 A5 JP 2003505362A5 JP 2001511410 A JP2001511410 A JP 2001511410A JP 2001511410 A JP2001511410 A JP 2001511410A JP 2003505362 A5 JP2003505362 A5 JP 2003505362A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- compound
- alkyl
- group
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 hydroxy, mercapto Chemical class 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 20
- 125000001424 substituent group Chemical group 0.000 description 14
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 8
- 229910052736 halogen Inorganic materials 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 150000002367 halogens Chemical class 0.000 description 5
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 4
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 108010003541 Platelet Activating Factor Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 description 3
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- YWXXLZKYWPWDLY-UHFFFAOYSA-N 4-[1-[[2-[3-chloro-4-(2-methylbenzoyl)anilino]phenyl]carbamoyloxy]ethoxy]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)OC(C)OC(=O)NC1=CC=CC=C1NC(C=C1Cl)=CC=C1C(=O)C1=CC=CC=C1C YWXXLZKYWPWDLY-UHFFFAOYSA-N 0.000 description 2
- JJSSWJLJQKHANC-UHFFFAOYSA-N 4-[[5-bromo-2-[3-chloro-4-(2-methylbenzoyl)anilino]phenyl]carbamoyloxymethoxy]-4-oxobutanoic acid Chemical compound CC1=CC=CC=C1C(=O)C(C(=C1)Cl)=CC=C1NC1=CC=C(Br)C=C1NC(=O)OCOC(=O)CCC(O)=O JJSSWJLJQKHANC-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940067594 flufenamate Drugs 0.000 description 2
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 201000005671 spondyloarthropathy Diseases 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- WQKHERPPDYPMNX-UHFFFAOYSA-N 6-chloro-3,4-dihydro-2h-naphthalen-1-one Chemical group O=C1CCCC2=CC(Cl)=CC=C21 WQKHERPPDYPMNX-UHFFFAOYSA-N 0.000 description 1
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 1
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 1
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 1
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical group [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 150000001925 cycloalkenes Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002343 gold Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14406399P | 1999-07-16 | 1999-07-16 | |
| US60/144,063 | 1999-07-16 | ||
| PCT/DK2000/000386 WO2001005749A1 (en) | 1999-07-16 | 2000-07-11 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003505362A JP2003505362A (ja) | 2003-02-12 |
| JP2003505362A5 true JP2003505362A5 (https=) | 2007-09-06 |
Family
ID=22506892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001511410A Pending JP2003505362A (ja) | 1999-07-16 | 2000-07-11 | ＩＬ−１βおよびＴＮＦ−αの抑制剤としてのアミノベンゾフェノン |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1202959B1 (https=) |
| JP (1) | JP2003505362A (https=) |
| KR (1) | KR20020022774A (https=) |
| CN (1) | CN1167667C (https=) |
| AT (1) | ATE277897T1 (https=) |
| AU (1) | AU768512B2 (https=) |
| CA (1) | CA2379286A1 (https=) |
| DE (1) | DE60014394T2 (https=) |
| ES (1) | ES2230118T3 (https=) |
| HU (1) | HUP0201911A3 (https=) |
| NZ (1) | NZ516825A (https=) |
| PL (1) | PL353646A1 (https=) |
| PT (1) | PT1202959E (https=) |
| RU (1) | RU2240995C2 (https=) |
| WO (1) | WO2001005749A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0301932A3 (en) | 2000-05-22 | 2007-09-28 | Leo Pharma As | Benzophenones as inhibitors of il-1 beta and tnf-alpha, pharmaceutical compositions containing them and use of them for producing pharmaceutical compositions |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7232924B2 (en) | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| EP1423356A2 (en) * | 2001-08-28 | 2004-06-02 | Leo Pharma A/S | Novel aminobenzoephenones |
| US20030225089A1 (en) * | 2002-04-10 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors |
| ES2278170T3 (es) | 2002-07-09 | 2007-08-01 | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG | Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias. |
| WO2004019873A2 (en) | 2002-08-29 | 2004-03-11 | Scios Inc. | Methods of promoting osteogenesis |
| CN1753861A (zh) * | 2002-12-20 | 2006-03-29 | 利奥制药有限公司 | 新颖的氨基二苯酮化合物 |
| DE602004027504D1 (de) * | 2003-07-24 | 2010-07-15 | Leo Pharma As | Aminobenzophenonverbindungen |
| WO2005030091A2 (en) | 2003-09-25 | 2005-04-07 | Scios Inc. | Stents and intra-luminal prostheses containing map kinase inhibitors |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| ES2341473T3 (es) | 2004-12-13 | 2010-06-21 | Leo Pharma A/S | Compuestos de aminobenzofenona sustituida con triazol. |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
| EP2315802A4 (en) * | 2008-07-31 | 2012-04-18 | 3M Innovative Properties Co | AZIUM COMPOSITIONS AND METHOD FOR THEIR PREPARATION AND USE |
| US8288005B2 (en) | 2008-07-31 | 2012-10-16 | 3M Innovative Properties Company | Fluoropolymer compositions and method of making and using thereof |
| EP2206534A1 (de) | 2008-10-09 | 2010-07-14 | c-a-i-r biosciences GmbH | Dibenzocycloheptanonderivate und pharmazeutische Mittel, welche diese Verbindungen enthalten |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1535401A (en) * | 1977-07-28 | 1978-12-13 | Holliday & Co Ltd L | Nitrodiphenylamine carboxylic acid disperse dyes |
| JPH0776303B2 (ja) * | 1986-11-21 | 1995-08-16 | 株式会社リコー | 呈色性フタリド化合物及びその製造法及びこのものを発色成分とした記録材料 |
| GB9701453D0 (en) * | 1997-01-24 | 1997-03-12 | Leo Pharm Prod Ltd | Aminobenzophenones |
-
2000
- 2000-07-11 AU AU58069/00A patent/AU768512B2/en not_active Ceased
- 2000-07-11 PT PT00943700T patent/PT1202959E/pt unknown
- 2000-07-11 RU RU2002103876/04A patent/RU2240995C2/ru not_active IP Right Cessation
- 2000-07-11 JP JP2001511410A patent/JP2003505362A/ja active Pending
- 2000-07-11 KR KR1020027000619A patent/KR20020022774A/ko not_active Ceased
- 2000-07-11 PL PL00353646A patent/PL353646A1/xx not_active Application Discontinuation
- 2000-07-11 NZ NZ516825A patent/NZ516825A/en unknown
- 2000-07-11 EP EP00943700A patent/EP1202959B1/en not_active Expired - Lifetime
- 2000-07-11 WO PCT/DK2000/000386 patent/WO2001005749A1/en not_active Ceased
- 2000-07-11 CA CA002379286A patent/CA2379286A1/en not_active Abandoned
- 2000-07-11 HU HU0201911A patent/HUP0201911A3/hu unknown
- 2000-07-11 ES ES00943700T patent/ES2230118T3/es not_active Expired - Lifetime
- 2000-07-11 DE DE60014394T patent/DE60014394T2/de not_active Expired - Fee Related
- 2000-07-11 CN CNB008121516A patent/CN1167667C/zh not_active Expired - Fee Related
- 2000-07-11 AT AT00943700T patent/ATE277897T1/de not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003505362A5 (https=) | ||
| RU2002103876A (ru) | АМИНОБЕНЗОФЕНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕРЛЕЙКИНА IL-1β И ФАКТОРА НЕКРОЗА ОПУХОЛЕЙ TNF-α | |
| JP2005501120A5 (https=) | ||
| JP2003505363A5 (https=) | ||
| WO2005115361A3 (en) | Androgen receptor modulators and method of treating disease using the same | |
| JP2004504301A5 (https=) | ||
| RU2002103867A (ru) | Аминобензофеноны как ингибиторы ИЛ-1 β и TNF-α | |
| JP2009522292A5 (https=) | ||
| RU2003102612A (ru) | N-окиси в качестве пролекарств производных 4-фенилпиридина, являющихся натагонистами рецептора nk-1 | |
| JP2007533722A5 (https=) | ||
| JP2012521428A5 (https=) | ||
| RU2002121646A (ru) | 1,3-дизамещенные пирролидины в качестве антагонистов альфа-2-адренорецепторов | |
| RU2007111711A (ru) | Производные трициклического лактама в качестве ингибиторов 11-бэта-гидроксистероидной дегидрогеназы | |
| RU2005138134A (ru) | Получение и применение арилалкильных производных кислот для лечения ожирения | |
| JP2014524934A5 (https=) | ||
| PE20060693A1 (es) | Nuevos derivados de trifluorometansulfonanilida oxamida eter | |
| MY147310A (en) | A solid pharmaceutical composition containing 2-ethoxy-1-{ [2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid or a salt thereof, a fat and oil-like substace having low melting point and a low viscosity binder | |
| RU2001124596A (ru) | Тиоамидные производные | |
| RU2002118113A (ru) | АМИНОБЕНЗОФЕНОНЫ КАК ИНГИБИТОРЫ ИЛ-1бета и ТНФ-альфа | |
| EP1756039A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE DISPOSAL OF ACTIVE SUBSTANCES | |
| RU2002103865A (ru) | Аминобензофеноны как ингибиторы ил-1β и TNF-α | |
| JP2006514611A5 (https=) | ||
| JP2005526696A5 (https=) | ||
| JP2005532331A5 (https=) | ||
| EP1877045A2 (en) | Methods of treating atherosclerosis |